巨星科技(002444.SZ):授權啟動發行H股並在香港聯交所上市的相關籌備工作
格隆匯10月17日丨巨星科技(002444.SZ)公佈,公司於2021年10月15日召開第五屆董事會第十三次會議,審議通過了《關於授權公司管理層啟動公司發行境外上市外資股(H股)並在香港聯合交易所有限公司上市相關籌備工作的議案》。為更好實施公司長期發展戰略,進一步提高公司的資本實力,完善公司境外融資渠道,加快公司全球化業務佈局,公司擬發行境外上市外資股(H股)並在香港聯合交易所有限公司上市。公司董事會授權公司管理層啟動H股上市的相關籌備工作,目前公司正與相關中介機構就本次H 股上市的相關工作進行商討,關於本次H股上市的具體細節尚未確定。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.